Phase Ib/Ii Open-Label, Randomised Evaluation Of Atezolizumab (Atezo) + Cpi-444 Vs Docetaxel As Second/Third-Line Therapy In Morpheus-Nsclc (Non-Small Cell Lung Cancer)E. Felip, F. L. Lim,M. Johnson,M. O'Brien, F. Barlesi,J. Mazieres,B. Solomon,V. Moreno,V. Boni,A. Swalduz,S. Goldberg,B. Keam,S. Allen,H-J. Helms, C. Shemesh, J. Pintoffl,N. Al-Sakaff,L. Bailey,P. Sayyed,B. C. ChoAnnals of Oncology（2020）引用 4|浏览59暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
